Arvest Bank Trust Division Decreases Stock Position in Boston Scientific Corporation $BSX

Arvest Bank Trust Division cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 52.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 59,608 shares of the medical equipment provider’s stock after selling 64,955 shares during the quarter. Arvest Bank Trust Division’s holdings in Boston Scientific were worth $5,684,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Murphy & Mullick Capital Management Corp raised its stake in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the second quarter worth about $26,000. United Community Bank raised its stake in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the last quarter. Colonial Trust Co SC grew its holdings in Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the period. Finally, Bangor Savings Bank grew its holdings in Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This represents a 16.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares in the company, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Jefferies Financial Group dropped their target price on Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Truist Financial dropped their price objective on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, April 23rd. Barclays dropped their price objective on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a report on Thursday, April 23rd. TD Cowen dropped their price objective on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Finally, Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $92.71.

Boston Scientific Price Performance

NYSE:BSX opened at $57.65 on Wednesday. Boston Scientific Corporation has a 52 week low of $52.52 and a 52 week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The stock’s fifty day moving average is $61.52 and its two-hundred day moving average is $79.54. The company has a market capitalization of $85.68 billion, a P/E ratio of 24.12, a P/E/G ratio of 1.06 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the previous year, the firm posted $0.75 earnings per share. The company’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific declared that its board has approved a stock buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.